You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 27, 2024

Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .

Details for ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2024)

Date Filed Document No. Description Snippet Link To Document
2024-02-02 1 Exhibit B (842 patent) O11085.6 A1 2, 2001 7,449,464 B2 11/2008 Martin et al. … (464 patent), # 2 Exhibit B (842 patent), # 3 Exhibit C (396 patent), # 4 Exhibit D (562 patent), # 5…United States Patent (10) Patent No.: … (45) Date of Patent: Jul. 2, 2013 (54) IMMEDIATE…6,514,983 B1 2/2003 Li et al. patent is extended or adjusted under 35 External link to document
2024-03-19 12 Text of Proposed Order Filed 03/19/24 Page 2 of 3 PageID: 310 Patent Nos. 7,449,464 and 8,859,562), and the same active ingredient…and involve the same Plaintiffs, two of the same patents (U.S. … 2 February 2024 3:24-cv-00641 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2024-03-27 13 Order AND ~Util - Create Case Association AND ~Util - Set/Clear Flags Filed 03/27/24 Page 2 of 3 PageID: 313 Patent Nos. 7,449,464 and 8,859,562), and the same active ingredient…and involve the same Plaintiffs, two of the same patents (U.S. … 2 February 2024 3:24-cv-00641 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2024-04-05 14 Answer to Complaint AND Counterclaim .S. Patent No. 7,449,464 (“’464 patent”), U.S. Patent No. 8,475,842 (“’842 patent”), U.S. Patent No. ….S. Patent No. 7,449,464 (“’464 patent”), U.S. Patent No. 8,475,842 (“’842 patent”), U.S. Patent No.…of U.S. Patent No. 7,449,464 (“the ’464 patent”); U.S. Patent No. 8,475,842 (“the ’842 patent”); U.S. …. Patent No. 8,859,562 (“the ’562 patent”); and U.S. Patent No. 11,633,396 (“the ’396 patent”). These …8,859,562 (“’562 patent”), and U.S. Patent No. 11,633,396 (“’396 patent”) (collectively, “Patents-in-Suit”) External link to document
2024-04-19 17 Answer to Counterclaim of U.S. Patent No. 7,449,464 (the “’464 Patent”), U.S. Patent No. 8,475,842 (the “’842 Patent”), and …and U.S. Patent No. 11,633,396 (“’396 Patent”). Plaintiffs deny that Kudos Pharmaceuticals Limited is the… the assignee of U.S. Patent No. 8,859,562 (the “’562 Patent”). The University of Sheffield is the assignee… by others of the Patents-in-Suit. PATENTS-IN-SUIT …issued the ’464 Patent on November 11, 2008. A true and correct copy of the ’464 Patent is attached to External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.